212 related articles for article (PubMed ID: 21189373)
1. WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children's oncology group study.
Perlman EJ; Grundy PE; Anderson JR; Jennings LJ; Green DM; Dome JS; Shamberger RC; Ruteshouser EC; Huff V
J Clin Oncol; 2011 Feb; 29(6):698-703. PubMed ID: 21189373
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.
Fernandez CV; Perlman EJ; Mullen EA; Chi YY; Hamilton TE; Gow KW; Ferrer FA; Barnhart DC; Ehrlich PF; Khanna G; Kalapurakal JA; Bocking T; Huff V; Tian J; Geller JI; Grundy PE; Anderson JR; Dome JS; Shamberger RC
Ann Surg; 2017 Apr; 265(4):835-840. PubMed ID: 27811504
[TBL] [Abstract][Full Text] [Related]
3. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Charles AK; Brown KW; Berry PJ
Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
[TBL] [Abstract][Full Text] [Related]
4. Stratification of Wilms tumor by genetic and epigenetic analysis.
Scott RH; Murray A; Baskcomb L; Turnbull C; Loveday C; Al-Saadi R; Williams R; Breatnach F; Gerrard M; Hale J; Kohler J; Lapunzina P; Levitt GA; Picton S; Pizer B; Ronghe MD; Traunecker H; Williams D; Kelsey A; Vujanic GM; Sebire NJ; Grundy P; Stiller CA; Pritchard-Jones K; Douglas J; Rahman N
Oncotarget; 2012 Mar; 3(3):327-35. PubMed ID: 22470196
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
Grundy P; Telzerow P; Moksness J; Breslow NE
Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
[TBL] [Abstract][Full Text] [Related]
6. Deletion of WT1 and WIT1 genes and loss of heterozygosity on chromosome 11p in Wilms tumors in Japan.
Kaneko Y; Takeda O; Homma C; Maseki N; Miyoshi H; Tsunematsu Y; Williams BG; Saunders GF; Sakurai M
Jpn J Cancer Res; 1993 Jun; 84(6):616-24. PubMed ID: 8393432
[TBL] [Abstract][Full Text] [Related]
7. Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features.
Sredni ST; Gadd S; Huang CC; Breslow N; Grundy P; Green DM; Dome JS; Shamberger RC; Beckwith JB; Perlman EJ;
Clin Cancer Res; 2009 Nov; 15(22):6800-9. PubMed ID: 19903788
[TBL] [Abstract][Full Text] [Related]
8. Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.
Brown KW; Power F; Moore B; Charles AK; Malik KT
Mol Cancer Res; 2008 Jul; 6(7):1114-23. PubMed ID: 18644976
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors.
Ruteshouser EC; Hendrickson BW; Colella S; Krahe R; Pinto L; Huff V
Genes Chromosomes Cancer; 2005 Jun; 43(2):172-80. PubMed ID: 15761866
[TBL] [Abstract][Full Text] [Related]
10. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
[TBL] [Abstract][Full Text] [Related]
11. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
Fernandez CV; Mullen EA; Chi YY; Ehrlich PF; Perlman EJ; Kalapurakal JA; Khanna G; Paulino AC; Hamilton TE; Gow KW; Tochner Z; Hoffer FA; Withycombe JS; Shamberger RC; Kim Y; Geller JI; Anderson JR; Grundy PE; Dome JS
J Clin Oncol; 2018 Jan; 36(3):254-261. PubMed ID: 29211618
[TBL] [Abstract][Full Text] [Related]
12. Identification of a new WT1 mutation in a sporadic Wilms' tumour.
Santos AC; Boavida MG; Costa A; Osorio-Almeida L
Biochim Biophys Acta; 1998 Aug; 1407(2):109-13. PubMed ID: 9685601
[TBL] [Abstract][Full Text] [Related]
13. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.
Gadd S; Huff V; Huang CC; Ruteshouser EC; Dome JS; Grundy PE; Breslow N; Jennings L; Green DM; Beckwith JB; Perlman EJ
Neoplasia; 2012 Aug; 14(8):742-56. PubMed ID: 22952427
[TBL] [Abstract][Full Text] [Related]
14. Loss of heterozygosity at 11p13 and 11p15 in Wilms tumor: a study of 22 cases from India.
Sigamani E; Wari MN; Iyer VK; Agarwala S; Sharma A; Bakhshi S; Dinda A
Pediatr Surg Int; 2013 Mar; 29(3):223-7. PubMed ID: 23292539
[TBL] [Abstract][Full Text] [Related]
15. Convergent evolution of 11p allelic loss in multifocal Wilms tumors arising in WT1 mutation carriers.
Valind A; Wessman S; Pal N; Karlsson J; Jonson T; Sandstedt B; Gisselsson D
Pediatr Blood Cancer; 2018 Nov; 65(11):e27301. PubMed ID: 29968962
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity at chromosome 11p15 in Wilms tumors: identification of two independent regions.
Karnik P; Chen P; Paris M; Yeger H; Williams BR
Oncogene; 1998 Jul; 17(2):237-40. PubMed ID: 9674708
[TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity at 11p13 in Wilms' tumours does not necessarily involve mutations in the WT1 gene.
Cowell JK; Groves N; Baird P
Br J Cancer; 1993 Jun; 67(6):1259-61. PubMed ID: 8390282
[TBL] [Abstract][Full Text] [Related]
18. Frequency of WT1 and 11p15 constitutional aberrations and phenotypic correlation in childhood Wilms tumour patients.
Segers H; Kersseboom R; Alders M; Pieters R; Wagner A; van den Heuvel-Eibrink MM
Eur J Cancer; 2012 Nov; 48(17):3249-56. PubMed ID: 22796116
[TBL] [Abstract][Full Text] [Related]
19. Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.
Watanabe N; Nakadate H; Haruta M; Sugawara W; Sasaki F; Tsunematsu Y; Kikuta A; Fukuzawa M; Okita H; Hata J; Soejima H; Kaneko Y
Genes Chromosomes Cancer; 2006 Jun; 45(6):592-601. PubMed ID: 16518847
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
